Inhibrx Stock Revenue Per Share

INBX Stock

USD 15.01 0.07 0.47%

Inhibrx fundamentals help investors to digest information that contributes to Inhibrx's financial success or failures. It also enables traders to predict the movement of Inhibrx Stock. The fundamental analysis module provides a way to measure Inhibrx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inhibrx stock.

		Last Reported	Projected for Next Year
	Revenue Per Share	0.04	0.04

Revenue Per Share is likely to drop to 0.04 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Inhibrx Company Revenue Per Share Analysis

Inhibrx's Revenue per Share is a ratio of total revenue earned per one share of common stock over a single fiscal year. It is calculated by dividing sales revenue earned over 12 months by the average number of outstanding shares. Revenue used in the calculation of this ratio is typically recorded when cash or cash equivalents are exchanged for services or goods.

Current Inhibrx Revenue Per Share

0.0363

Most of Inhibrx's fundamental indicators, such as Revenue Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inhibrx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Inhibrx Revenue Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Inhibrx is extremely important. It helps to project a fair market value of Inhibrx Stock properly, considering its historical fundamentals such as Revenue Per Share. Since Inhibrx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inhibrx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inhibrx's interrelated accounts and indicators.

	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Current Assets	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Deferred Long Term Liab	Capital Stock	Common Stock	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.72	0.65	0.81	0.14	0.81	0.98	-0.71	-0.94	0.68	-0.02	0.5	0.84	-0.59	0.82	-0.78	-0.49	0.91	0.91	0.67	0.63
Retained Earnings	-0.72		-0.63	-0.97	-0.17	-0.97	-0.7	0.57	0.76	-0.97	0.26	-0.87	-0.94	0.75	-0.96	0.59	0.81	-0.83	-0.83	-0.97	-0.9
Accounts Payable	0.65	-0.63		0.69	0.68	0.71	0.76	-0.3	-0.85	0.56	-0.2	0.6	0.66	-0.72	0.68	-0.82	-0.3	0.71	0.71	0.5	0.52
Total Current Assets	0.81	-0.97	0.69		0.18	1.0	0.81	-0.62	-0.85	0.97	-0.36	0.86	0.99	-0.76	1.0	-0.71	-0.72	0.86	0.86	0.96	0.9
Property Plant Equipment	0.14	-0.17	0.68	0.18		0.21	0.28	0.46	-0.38	0.07	-0.12	0.21	0.1	-0.68	0.17	-0.63	0.06	0.11	0.11	-0.03	0.0
Total Assets	0.81	-0.97	0.71	1.0	0.21		0.81	-0.6	-0.86	0.97	-0.36	0.87	0.99	-0.78	1.0	-0.73	-0.72	0.85	0.85	0.95	0.89
Total Stockholder Equity	0.98	-0.7	0.76	0.81	0.28	0.81		-0.65	-0.98	0.67	-0.08	0.53	0.83	-0.65	0.82	-0.87	-0.41	0.9	0.9	0.63	0.62
Current Deferred Revenue	-0.71	0.57	-0.3	-0.62	0.46	-0.6	-0.65		0.59	-0.59	-0.08	-0.39	-0.67	0.04	-0.64	0.27	0.47	-0.76	-0.76	-0.64	-0.61
Net Debt	-0.94	0.76	-0.85	-0.85	-0.38	-0.86	-0.98	0.59		-0.72	0.16	-0.62	-0.87	0.73	-0.86	0.89	0.45	-0.91	-0.91	-0.68	-0.67
Long Term Debt	0.68	-0.97	0.56	0.97	0.07	0.97	0.67	-0.59	-0.72		-0.43	0.9	0.96	-0.71	0.97	-0.59	-0.75	0.76	0.76	0.99	0.93
Net Receivables	-0.02	0.26	-0.2	-0.36	-0.12	-0.36	-0.08	-0.08	0.16	-0.43		-0.42	-0.38	0.33	-0.38	0.31	0.15	0.08	0.08	-0.38	-0.28
Total Liab	0.5	-0.87	0.6	0.86	0.21	0.87	0.53	-0.39	-0.62	0.9	-0.42		0.83	-0.77	0.86	-0.51	-0.49	0.69	0.69	0.87	0.95
Net Invested Capital	0.84	-0.94	0.66	0.99	0.1	0.99	0.83	-0.67	-0.87	0.96	-0.38	0.83		-0.72	0.99	-0.7	-0.69	0.87	0.87	0.95	0.89
Short Long Term Debt	-0.59	0.75	-0.72	-0.76	-0.68	-0.78	-0.65	0.04	0.73	-0.71	0.33	-0.77	-0.72		-0.76	0.81	0.39	-0.6	-0.6	-0.63	-0.67
Net Working Capital	0.82	-0.96	0.68	1.0	0.17	1.0	0.82	-0.64	-0.86	0.97	-0.38	0.86	0.99	-0.76		-0.73	-0.69	0.86	0.86	0.95	0.9
Short Term Debt	-0.78	0.59	-0.82	-0.71	-0.63	-0.73	-0.87	0.27	0.89	-0.59	0.31	-0.51	-0.7	0.81	-0.73		0.25	-0.65	-0.65	-0.5	-0.47
Deferred Long Term Liab	-0.49	0.81	-0.3	-0.72	0.06	-0.72	-0.41	0.47	0.45	-0.75	0.15	-0.49	-0.69	0.39	-0.69	0.25		-0.54	-0.54	-0.79	-0.56
Capital Stock	0.91	-0.83	0.71	0.86	0.11	0.85	0.9	-0.76	-0.91	0.76	0.08	0.69	0.87	-0.6	0.86	-0.65	-0.54		1.0	0.76	0.81
Common Stock	0.91	-0.83	0.71	0.86	0.11	0.85	0.9	-0.76	-0.91	0.76	0.08	0.69	0.87	-0.6	0.86	-0.65	-0.54	1.0		0.76	0.81
Long Term Debt Total	0.67	-0.97	0.5	0.96	-0.03	0.95	0.63	-0.64	-0.68	0.99	-0.38	0.87	0.95	-0.63	0.95	-0.5	-0.79	0.76	0.76		0.93
Capital Surpluse	0.63	-0.9	0.52	0.9	0.0	0.89	0.62	-0.61	-0.67	0.93	-0.28	0.95	0.89	-0.67	0.9	-0.47	-0.56	0.81	0.81	0.93

Click cells to compare fundamentals

Inhibrx Revenue Per Share Historical Pattern

Today, most investors in Inhibrx Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Inhibrx's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Inhibrx revenue per share as a starting point in their analysis.

Inhibrx Revenue Per Share

Timeline

Revenue per share does not take into account any of company expenses and is helpful only when comparing relative sale figures within a given industry.

Competition

Predict Inhibrx

Revenue Per Share Over Time

Inhibrx Common Stock Shares Outstanding

Common Stock Shares Outstanding

38.17 Million

At this time, Inhibrx's Common Stock Shares Outstanding is fairly stable compared to the past year.

Inhibrx Revenue Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inhibrx's direct or indirect competition against its Revenue Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inhibrx could also be used in its relative valuation, which is a method of valuing Inhibrx by comparing valuation metrics of similar companies.

Inhibrx is currently under evaluation in revenue per share category among its peers.

Inhibrx ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inhibrx's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inhibrx's managers, analysts, and investors.

Environmental

Governance

Social

Inhibrx Fundamentals

	Return On Equity	-20.31
	Return On Asset	-0.57
	Profit Margin	1,020 %
	Current Valuation	15.26 M
	Shares Outstanding	14.48 M
	Shares Owned By Insiders	23.54 %
	Shares Owned By Institutions	67.49 %
	Number Of Shares Shorted	1.2 M
	Price To Book	1.18 X
	Price To Sales	124.34 X
	Revenue	1.8 M
	Gross Profit	(107.99 M)
	EBITDA	(206.69 M)
	Net Income	(241.36 M)
	Cash And Equivalents	176.38 M
	Cash Per Share	4.52 X
	Total Debt	210.14 M
	Debt To Equity	4.22 %
	Current Ratio	7.51 X
	Book Value Per Share	15.15 X
	Cash Flow From Operations	(193.31 M)
	Short Ratio	14.06 X
	Earnings Per Share	119.39 X
	Target Price	15.0
	Number Of Employees	166
	Beta	2.88
	Market Capitalization	209.76 M
	Total Asset	307.89 M
	Retained Earnings	(613.73 M)
	Working Capital	239.05 M
	Net Asset	307.89 M

About Inhibrx Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inhibrx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibrx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibrx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC